Seegene is playing a critical role in developing effective testing solution to mitigate the spread of rapidly mutating COVID-19 and variants.
Full screening for SARS-CoV-2 and variants
including the five notable mutations in S gene
Detection and differentiation of three mutation sites in S gene
for identification of SARS-CoV-2 variants
Seegene utilizes bioinformatics (SG-Insilico™) to monitor newly emerging SARS-CoV-2 sequence information on a regular basis and design optimized diagnostic assay.
Allplex™ SARS-CoV-2 Master Assay can be used alone or expanded to syndromic test with respiratory essential panel for common respiratory infections, including influenza A and B, metapneumovirus, parainfluenza virus 1/2/3/4, adenovirus, rhinovirus A/B/C and respiratory syncytial virus A/B, to provide more insights for diagnosis of symptomatic patients especially with the emerging SARS-CoV-2 variants.
Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay is designed to detect and differentiate between SARS-CoV-2, influenza A, influenza B and RSV
for primary screening during the upcoming flu season.
- The endogenous and exogenous internal controls are designed to verify the entire process from sample collection to nucleic acid extraction and PCR steps
- The endogenous internal control enables validating correct sampling for self-collected specimens
Multiplex real-time PCR with high sensitivity and specificity by utilization of Seegene’s proprietary technologies
Detecting N, S, RdRP and/or E target genes of SARS-CoV-2 to minimize the risk of genetic variations and allow high accuracy
No cross-reactivity confirmed with respiratory pathogens including SARS, MERS and SARS-related viruses
Seegene is supporting extensive clinical studies in multi-sites and multi-nation on a combined test of the most common respiratory viruses and SARS-CoV-2 from influenza like illness patient’s specimens.
It would help meet the global interests and needs for a comprehensive understanding of the syndromic test related to respiratory pathogens including SARS-CoV-2. The program is designed to simply visualize the prevalence of pathogens and demonstrate cases of multiple pathogens infection.
*Overseas Validation Experiments for Respiratory virus & Coronavirus co-testing in Multi-center, Multi-nation
With Seegene’s core technologies and proprietary know-hows, enhance your MDx products with incomparable performance and usability.
Enables rapid designing of high multiplex oligos using Seegene-developed algorithms and confidential variables.
Allows the implementation of high multiplex diagnostics with unparalleled specificity using Seegene’s unique primer structure.
Achieves accurate target signals by independently controlling multiple target signals for primer and probe annealing temperatures.
Broadens capacity for high multiplex target detection & quantification by enabling analysis of multiple Ct values in a single detection channel.
Enables accurate reporting of target’s positive or negative results through Seegene’s proprietary signal processing algorithms.
 Allplex™ 2019-nCoV Assay has not been FDA cleared or approved. This test has been authorized by FDA under an emergency use authorization for use by authorized laboratories. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner.
 Allplex™ SARS-CoV-2/Flu A/Flu B/RSV Assay, SARS-CoV-2 Assay and RV Essential Assay are intended for in vitro diagnostic use in Europe and not available in all countries.